Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 1,019 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $83.98, for a total transaction of $85,575.62. Following the completion of the sale, the vice president owned 33,682 shares of the company’s stock, valued at approximately $2,828,614.36. This trade represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of EW opened at $83.32 on Tuesday. The company has a market cap of $48.04 billion, a price-to-earnings ratio of 44.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $82.08 and a two-hundred day moving average of $82.54.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on EW shares. The Goldman Sachs Group restated a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Sigma Planning Corp raised its position in shares of Edwards Lifesciences by 8.2% in the first quarter. Sigma Planning Corp now owns 3,806 shares of the medical research company’s stock worth $305,000 after acquiring an additional 288 shares during the period. Checchi Capital Advisers LLC raised its position in shares of Edwards Lifesciences by 22.1% in the first quarter. Checchi Capital Advisers LLC now owns 4,511 shares of the medical research company’s stock worth $361,000 after acquiring an additional 815 shares during the period. Nwam LLC raised its position in shares of Edwards Lifesciences by 2.8% in the first quarter. Nwam LLC now owns 32,909 shares of the medical research company’s stock worth $2,635,000 after acquiring an additional 904 shares during the period. Calamos Advisors LLC raised its position in shares of Edwards Lifesciences by 2.3% in the first quarter. Calamos Advisors LLC now owns 166,828 shares of the medical research company’s stock worth $13,360,000 after acquiring an additional 3,763 shares during the period. Finally, AMG National Trust Bank raised its position in shares of Edwards Lifesciences by 1.2% in the first quarter. AMG National Trust Bank now owns 76,372 shares of the medical research company’s stock worth $6,116,000 after acquiring an additional 900 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.